Storia in 5 fonti

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.

originale

Timeline cronologica

lunedì 8 giugno 2026·biopharmadive.com
Roche stakes $700M on Nurix’s protein-degrading drug
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
lunedì 8 giugno 2026·swissinfo.ch
Roche joins Californian Nurix oncology programme
Roche pledges $700 million to join research on the drug bexobrutideg.

biopharmadive.com

1 mese fa

Roche stakes $700M on Nurix’s protein-degrading drug

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

Leggi questa versione → originale

swissinfo.ch1 mese fa

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental blood-cancer drug, betting it can help patients whose disease stops responding to existing…

Leggi questa versione → originale

benzinga.com1 mese fa

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T

Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.

Leggi questa versione → originale

investors.com1 mese fa

Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying

Shares bounded off their 50-day line Monday after inking a deal with Roche for a BTK-degrading drug.

Leggi questa versione → originale

lunedì 8 giugno 2026·

swissinfo.ch

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental blood-cancer drug, betting it can help patients whose…

lunedì 8 giugno 2026·

endpoints.news

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.

lunedì 8 giugno 2026·

benzinga.com

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T

Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.

lunedì 8 giugno 2026·

investors.com

Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying

Shares bounded off their 50-day line Monday after inking a deal with Roche for a BTK-degrading drug.

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Timeline cronologica

Roche stakes $700M on Nurix’s protein-degrading drug

Roche joins Californian Nurix oncology programme

Roche stakes $700M on Nurix’s protein-degrading drug

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T

Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T

Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying